{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T19:07:25Z","timestamp":1790017645467,"version":"4.0.1"},"reference-count":47,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T00:00:00Z","timestamp":1773014400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Immune exclusion is a major barrier to immune checkpoint inhibitor (ICI) efficacy in gastric cancer, yet the spatial mechanisms by which m\n                      <jats:sup>6<\/jats:sup>\n                      A regulators drive this phenotype remain unclear.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We integrated single-cell RNA-seq, spatial transcriptomics, and functional assays to map the gastric cancer microenvironment and derived an m\n                      <jats:sup>6<\/jats:sup>\n                      A regulator score to quantify the spatial coupling between m\n                      <jats:sup>6<\/jats:sup>\n                      A patterns and immune exclusion.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      CAFs emerged as a central hub that excluded T cells via collagen\u2013integrin interactions and MIF signaling, forming a CAF-defined collagen barrier that impeded CD8\n                      <jats:sup>+<\/jats:sup>\n                      T-cell entry into the tumor core. In immune-excluded samples, m\n                      <jats:sup>6<\/jats:sup>\n                      A regulator scores were selectively elevated in tumor nests compared with surrounding stroma. Across five bulk transcriptomic datasets, this phenotype was associated with reduced predicted ICI responsiveness, activation of chemotherapy resistance programs, and poor survival. Mechanistically, FTO was highly expressed in the immune-excluded phenotype and correlated with stromal activation and T-cell exclusion. Serial immunohistochemistry and multiplex immunofluorescence revealed high FMR1 protein expression in immune-excluded tumors, with CD8\n                      <jats:sup>+<\/jats:sup>\n                      T cells largely confined to the stroma. Cycloheximide (CHX) chase and MG132 treatment showed that FMR1 depletion reduced FTO protein abundance and accelerated FTO turnover in an MG132-sensitive manner, consistent with a post-translational regulatory relationship.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Collectively, our data support an FMR1\u2013FTO module associated with the immune-excluded phenotype and nominate this axis as a potential vulnerability for disrupting stromal immune barriers. The FMR1\u2013FTO axis may represent a candidate target for strategies aimed at relieving immune exclusion and improving immunotherapy sensitivity.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1713267","type":"journal-article","created":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T06:47:22Z","timestamp":1773038842000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["Integrative single-cell, spatial, and bulk transcriptomics reveal an FMR1\u2013FTO axis linked to the immune-excluded phenotype in gastric cancer"],"prefix":"10.3389","volume":"17","author":[{"given":"Chenxi","family":"Mao","sequence":"first","affiliation":[{"name":"The Affiliated Lianyungang Hospital of Xuzhou Medical University","place":["Lianyungang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miao","family":"Zhang","sequence":"additional","affiliation":[{"name":"The Affiliated Lianyungang Hospital of Xuzhou Medical University","place":["Lianyungang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kangjie","family":"Zhou","sequence":"additional","affiliation":[{"name":"The Affiliated Lianyungang Hospital of Xuzhou Medical University","place":["Lianyungang, China"]},{"name":"Lianyungang Clinical College of Nanjing Medical University","place":["Lianyungang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yidong","family":"Hong","sequence":"additional","affiliation":[{"name":"The Affiliated Lianyungang Hospital of Xuzhou Medical University","place":["Lianyungang, China"]},{"name":"Lianyungang Clinical College of Nanjing Medical University","place":["Lianyungang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiqian","family":"Han","sequence":"additional","affiliation":[{"name":"Lianyungang Clinical College of Nanjing Medical University","place":["Lianyungang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luming","family":"Zhao","sequence":"additional","affiliation":[{"name":"The Affiliated Lianyungang Hospital of Xuzhou Medical University","place":["Lianyungang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingtong","family":"Liang","sequence":"additional","affiliation":[{"name":"Lianyungang Clinical College of Nanjing Medical University","place":["Lianyungang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingzhou","family":"Zhang","sequence":"additional","affiliation":[{"name":"The Affiliated Lianyungang Hospital of Xuzhou Medical University","place":["Lianyungang, China"]},{"name":"Lianyungang Clinical College of Nanjing Medical University","place":["Lianyungang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Hu","sequence":"additional","affiliation":[{"name":"The Affiliated Lianyungang Hospital of Xuzhou Medical University","place":["Lianyungang, China"]},{"name":"Lianyungang Clinical College of Nanjing Medical University","place":["Lianyungang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fenglei","family":"Wu","sequence":"additional","affiliation":[{"name":"The Affiliated Lianyungang Hospital of Xuzhou Medical University","place":["Lianyungang, China"]},{"name":"Lianyungang Clinical College of Nanjing Medical University","place":["Lianyungang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,3,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA A Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(25)00052-2","article-title":"Gastric cancer","volume":"405","author":"Sundar","year":"2025","journal-title":"Lancet"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/nature13480","article-title":"Comprehensive molecular characterization of gastric adenocarcinoma","volume":"513","year":"2014","journal-title":"Nature"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25052649","article-title":"Molecular classifications in gastric cancer: A call for interdisciplinary collaboration","volume":"25","author":"D\u00edaz Del Arco","year":"2024","journal-title":"IJMS"},{"key":"B5","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1001\/jamaoncol.2021.0275","article-title":"Assessment of pembrolizumab therapy for the treatment of microsatellite instability\u2013high gastric or gastroesophageal junction cancer among patients in the KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 clinical trials","volume":"7","author":"Chao","year":"2021","journal-title":"JAMA Oncol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","article-title":"First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial","volume":"398","author":"Janjigian","year":"2021","journal-title":"Lancet"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31827-5","article-title":"Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"390","author":"Kang","year":"2017","journal-title":"Lancet"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)31257-1","article-title":"Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial","volume":"392","author":"Shitara","year":"2018","journal-title":"Lancet"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0101-z","article-title":"Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer","volume":"24","author":"Kim","year":"2018","journal-title":"Nat Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2017.88","article-title":"Monitoring immune-checkpoint blockade: response evaluation and biomarker development","volume":"14","author":"Nishino","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-1507","article-title":"The where, the when, and the how of immune monitoring for cancer immunotherapies in the era of checkpoint inhibition","volume":"22","author":"Hegde","year":"2016","journal-title":"Clin Cancer Res"},{"key":"B12","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1111\/imr.13178","article-title":"Neutrophil interactions with T cells, platelets, endothelial cells, and of course tumor cells","volume":"314","author":"Segal","year":"2023","journal-title":"Immunol Rev"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1111\/imr.13032","article-title":"Diving into the mechanism of action of tumor immunotherapies with intravital imaging*","volume":"306","author":"Bousso","year":"2022","journal-title":"Immunol Rev"},{"key":"B14","doi-asserted-by":"publisher","first-page":"e002467","DOI":"10.1136\/jitc-2021-002467","article-title":"Tumor microenvironment evaluation promotes precise checkpoint immunotherapy of advanced gastric cancer","volume":"9","author":"Zeng","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1016817","article-title":"Tumor microenvironment-mediated immune tolerance in development and treatment of gastric cancer","volume":"13","author":"Liu","year":"2022","journal-title":"Front Immunol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3390\/ijms242015321","article-title":"Predictive biomarkers for immunotherapy in gastric cancer: current status and emerging prospects","volume":"24","author":"Hou","year":"2023","journal-title":"IJMS"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-18-0436","article-title":"Tumor microenvironment characterization in gastric cancer identifies prognostic and immunotherapeutically relevant gene signatures","volume":"7","author":"Zeng","year":"2019","journal-title":"Cancer Immunol Res"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-21-0683","article-title":"Single-cell atlas of lineage states, tumor microenvironment, and subtype-specific expression programs in gastric cancer","volume":"12","author":"Kumar","year":"2022","journal-title":"Cancer Discov"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s12276-018-0071-8","article-title":"Single-cell RNA sequencing technologies and bioinformatics pipelines","volume":"50","author":"Hwang","year":"2018","journal-title":"Exp Mol Med"},{"key":"B20","doi-asserted-by":"publisher","first-page":"e000155","DOI":"10.1136\/jitc-2019-000155","article-title":"The Society for Immunotherapy of Cancer statement on best practices for multiplex immunohistochemistry (IHC) and immunofluorescence (IF) staining and validation","volume":"8","author":"Taube","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B21","doi-asserted-by":"publisher","first-page":"98","DOI":"10.4143\/crt.2019.195","article-title":"High-throughput multiplex immunohistochemical imaging of the tumor and its microenvironment","volume":"52","author":"Koh","year":"2020","journal-title":"Cancer Res Treat"},{"key":"B22","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/s41392-020-00450-x","article-title":"The role of m6A modification in the biological functions and diseases","volume":"6","author":"Jiang","year":"2021","journal-title":"Sig Transduct Target Ther"},{"key":"B23","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1038\/nsmb.3162","article-title":"N6-methyladenosine\u2013encoded epitranscriptomics","volume":"23","author":"Liu","year":"2016","journal-title":"Nat Struct Mol Biol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1038\/s41419-017-0129-x","article-title":"N6-methyladenosine links RNA metabolism to cancer progression","volume":"9","author":"Dai","year":"2018","journal-title":"Cell Death Dis"},{"key":"B25","doi-asserted-by":"publisher","first-page":"e12921","DOI":"10.1111\/cpr.12921","article-title":"N6 -methyladenosine (m6 A) RNA modification in human cancer","volume":"53","author":"Huo","year":"2020","journal-title":"Cell Proliferation"},{"key":"B26","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1038\/s41419-021-03585-z","article-title":"Emerging role of RNA modification N6-methyladenosine in immune evasion","volume":"12","author":"Lou","year":"2021","journal-title":"Cell Death Dis"},{"key":"B27","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.ccell.2020.04.017","article-title":"Targeting FTO suppresses cancer stem cell maintenance and immune evasion","volume":"38","author":"Su","year":"2020","journal-title":"Cancer Cell"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.2174\/0113862073299882240530051559","article-title":"FTO is associated with patient prognosis and immune infiltrates in gastric cancer and regulates TGF-\u03b2 Expression","volume":"28","author":"Lai","year":"2025","journal-title":"CCHTS"},{"key":"B29","doi-asserted-by":"publisher","first-page":"eabl7207","DOI":"10.1126\/science.abl7207","article-title":"Aberrant hyperexpression of the RNA binding protein FMRP in tumors mediates immune evasion","volume":"378","author":"Zeng","year":"2022","journal-title":"Science"},{"key":"B30","doi-asserted-by":"publisher","first-page":"36687","DOI":"10.1038\/s41598-025-20551-3","article-title":"\u200bIdentification of a novel m6A RNA methylation regulator-based signature for prognosis and immune landscape prediction in hepatocellular carcinoma","volume":"15","author":"Wang","year":"2025","journal-title":"Sci Rep"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.819515","article-title":"Fatty acid metabolic signaling pathway alternation predict prognosis of immune checkpoint inhibitors in glioblastoma","volume":"13","author":"Liu","year":"2022","journal-title":"Front Immunol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.05.3314","article-title":"Immunosurveillance and survivin-specific T-cell immunity in children with high-risk neuroblastoma","volume":"24","author":"Coughlin","year":"2006","journal-title":"JCO"},{"key":"B33","doi-asserted-by":"publisher","first-page":"17031","DOI":"10.1038\/s41598-017-16987-x","article-title":"Multiplex three-dimensional optical mapping of tumor immune microenvironment","volume":"7","author":"Lee","year":"2017","journal-title":"Sci Rep"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3892\/or.2017.5904","article-title":"FTO expression is associated with the occurrence of gastric cancer and prognosis","volume":"38","author":"Xu","year":"2017","journal-title":"Oncol Rep"},{"key":"B35","doi-asserted-by":"publisher","first-page":"99","DOI":"10.2144\/btn-2022-0034","article-title":"Western blotting (immunoblotting): history, theory, uses, protocol and problems","volume":"75","author":"Sule","year":"2023","journal-title":"BioTechniques"},{"key":"B36","doi-asserted-by":"publisher","first-page":"58","DOI":"10.2144\/btn-2022-0003","article-title":"Western blotting: A powerful staple in scientific and biomedical research","volume":"73","author":"Begum","year":"2022","journal-title":"BioTechniques"},{"key":"B37","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/978-1-0716-3143-0_6","article-title":"Co-Immunoprecipitation (Co-Ip) in Mammalian Cells","volume-title":"Polycomb Group Proteins. Methods in Molecular Biology","author":"Lo Sardo","year":"2023"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1038\/s41596-020-0312-x","article-title":"The HDOCK server for integrated protein\u2013protein docking","volume":"15","author":"Yan","year":"2020","journal-title":"Nat Protoc"},{"key":"B39","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.softx.2015.06.001","article-title":"GROMACS: High performance molecular simulations through multi-level parallelism from laptops to supercomputers","author":"Abraham","year":"2015","journal-title":"SoftwareX"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2016.03.021","article-title":"The m 6 A methyltransferase METTL3 promotes translation in human cancer cells","volume":"62","author":"Lin","year":"2016","journal-title":"Mol Cell"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1038\/nature25501","article-title":"TGF\u03b2 attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells","volume":"554","author":"Mariathasan","year":"2018","journal-title":"Nature"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1080\/15476286.2020.1809186","article-title":"RNA-binding proteins in neurological development and disease","volume":"18","author":"Prashad","year":"2021","journal-title":"RNA Biol"},{"key":"B43","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s40164-022-00298-7","article-title":"Role of m6A writers, erasers and readers in cancer","volume":"11","author":"Fang","year":"2022","journal-title":"Exp Hematol Oncol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23073800","article-title":"FTO m6A demethylase in obesity and cancer: implications and underlying molecular mechanisms","volume":"23","author":"Azzam","year":"2022","journal-title":"IJMS"},{"key":"B45","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1038\/s41419-022-04503-7","article-title":"N6-methyladenosine demethylase FTO promotes growth and metastasis of gastric cancer via m6A modification of caveolin-1 and metabolic regulation of mitochondrial dynamics","volume":"13","author":"Zhou","year":"2022","journal-title":"Cell Death Dis"},{"key":"B46","doi-asserted-by":"publisher","first-page":"2782","DOI":"10.1038\/s41467-019-10669-0","article-title":"m6A mRNA demethylase FTO regulates melanoma tumorigenicity and response to anti-PD-1 blockade","volume":"10","author":"Yang","year":"2019","journal-title":"Nat Commun"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2020.06.153","article-title":"RNA N6-methyladenosine demethylase FTO regulates PD-L1 expression in colon cancer cells","volume":"530","author":"Tsuruta","year":"2020","journal-title":"Biochem Biophys Res Commun"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1713267\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T06:47:26Z","timestamp":1773038846000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1713267\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,9]]},"references-count":47,"alternative-id":["10.3389\/fimmu.2026.1713267"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1713267","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,9]]},"article-number":"1713267"}}